GlassScriptPhysician profile
Juan A Lacson
NPI 1831153055
$4,667.77
in general payments reported to CMS, 2019-2025
19 companies · $794 in 2025
The $794 reported for 2025 was more than what 76% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $538 · 2020: $201 · 2021: $680 · 2022: $693 · 2023: $1,123 · 2024: $638 · 2025: $794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,554.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,612.10 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Gilead Sciences, INC. | $1,327.09 | 2019-2025 | Biktarvy, Sunlenca |
| Insmed, INC. | $476.13 | 2020-2025 | Arikayce |
| Merck Sharp & Dohme LLC | $269.41 | 2019-2025 | Pifeltro, Dificid, Zerbaxa |
| Paratek Pharmaceuticals, INC. | $242.30 | 2021-2025 | Nuzyra |
| Janssen Biotech, INC. | $173.06 | 2019-2023 | Symtuza |
| Abbvie INC. | $165.65 | 2022-2025 | |
| Amgen INC. | $90.39 | 2021-2025 | Evenity, Prolia, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $72.57 | 2023 | Cuvitru |
| Aimmune Therapeutics, INC. | $50.63 | 2024-2025 | Vowst |
| Melinta Therapeutics, LLC | $43.90 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $26.06 | 2023 | Symtuza |
| Organogenesis INC. | $21.62 | 2023 | Puraply |
| Lilly USA, LLC | $21.34 | 2024 | Mounjaro |
| Cumberland Pharmaceuticals, INC. | $17.71 | 2023 | Vibativ |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $16.77 | 2022 | |
| Emd Serono, INC. | $15.44 | 2025 | |
| La Jolla Pharmaceutical Company | $14.75 | 2023 | Xerava |
| Cashflow Solutions, LLC | $10.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Lacson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.